Results of a prospective phase II trial with ofatumumab as part of reduced intensity conditioning regimen in high‐risk non‐Hodgkin B lymphoma patients: A GELTAMO trial. (June 2017) - Cabrero, M.; Lopez‐Corral, L.; de la Cruz, F.; Jarque, I.; Valcarcel, D.; Perez‐Lopez, E.; Martin, A.; Sanchez‐Guijo, F.; Grande, C.; Martin‐Calvo, M.; Martin, A.; Caballero, D.